MyDx Secures City and State Legal Cannabis Manufacturing and Distribution for Its MyDx360 Customers
MyDx360 Customers in California Now Have Access to One of the First Legally Licensed Cannabis Manufacturing and Distribution Facilities Located in the City of San Diego
San Diego, California--(Newsfile Corp. - September 19, 2018) - MyDx, Inc. (OTC Pink: MYDX) ("MyDx" or the "Company"), a leader in science based cannabis health technologies and creator of the industry's first handheld, multi-use chemical analyzer to help consumers and professionals understand how cannabis makes cannabis users feel, announced today it is excited to launch its first MyDx360 customers into the California legal cannabis market.
Figure 1: MyDx Secures City and State Legal Cannabis Manufacturing and Distribution
Cannot view Figure 1? Please visit:
https://s.yimg.com/os/en-US/homerun/newsfile_64/a86620e53365097794903d1d6ba8ea34
In order to provide a complete and seamless product offering for MyDx360 customers, starting with the development of custom oil formulations based on the MyDx Database, as well as supplying the EcoSmartPenTM technology suite to track consumer feedback, MyDx360 customers who have developed proprietary product formulations powered by MyDx are now able to seamlessly transition themselves into full scale legal manufacturing and distribution of cannabis in the State of California through this new partnership.
After months of diligence, MyDx has completed its research into the San Diego legal manufacturing and distribution license holder marketplace. Having reviewed the varying degrees of license approval status that many groups currently hold, MyDx has confirmed the positive approval at both the city and state level of a reputable, legally licensed, manufacturing and distribution partner it has signed an agreement with to support the products developed by MyDx360 customers.
With this complete service, formulated products developed for MyDx360 customers are now able to be fully integrated into the California Cannabis Track-and-Trace (CCTT) system that records the inventory and movement of cannabis products from production to sale.
"MyDx is very excited to now focus on combining what we believe is the most advanced dataset in the industry with our cutting edge scientists and R&D formulators to continue to innovate products for MyDx360 customers working towards maximal impact and satisfaction for their customer base," stated Daniel Yazbeck, Chief Executive Officer of MyDx.
Stay tuned to the coming developments as companies move towards entering the legal 2018 California Marketplace.
Learn More - MYDX360: www.mydxlife.com/mydx360.
About MyDx, Inc.
MyDx, Inc. (OTC Pink: MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company's first product, MyDx®, also known as "My Diagnostic", is a patented multiuse hand-held chemical analyzer designed to help consumers and professionals test for pesticides in food, chemicals in water, toxins in the air, and the safety and potency of cannabis samples, which is the Company's initial focus of through the CannaDxTM application. CannaDx users have submitted over 40,000 crowdsourced records revealing the chemical profile of the cannabis they are consuming and how it makes them feel which feeds our data analytics platform, the MyDx360 SaaS business, as well as the biopharmaceutical division of MyDx. The Company is committed to addressing areas of critical national need to promote public safety, transparency and regulation in the various markets we serve and hence its more immediate mission is to continue to develop smart devices as part of an ecosystem that crowdsources consumer-generated preclinical data to drive innovation in the cannabis industry. For more information, please visit www.mydxlife.com.
Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.
Investor Contact:
MyDx Shareholder Communications
800.814.4550 ext. 4
ir@mydxlife.com
